Novo Nordisk A/S NVO
NYSE
$38.06-0.52 (-1.35%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
The Danish drugmaker promised new blockbuster medicines and expanded pill capacity, but investors wanted a clearer measure of growth before patents expire.
The Danish drugmaker is pairing a consumer-facing rebrand with a culture reset as Eli Lilly widens its lead in obesity medicines.
Novo Nordisk is shortening its public name as it prepares investors for a sharper strategic push in the obesity-drug race.
NVO is in the latest 13F portfolio of 1 of the gurus we follow.